Regina Rabinovich, director of the Malaria Elimination Initiative at ISGlobal, has been elected board chair of The Sabin Vaccine Institute, a leading advocate for making vaccines more accessible, enabling innovation and expanding immunization across the globe. Rabinovich has served on the board since November 2015, and as chair of the Governance Committee since 2016.
A Career Dedicated to Global Health
Rabinovich has deep global health expertise, with more than three decades of experience in the health and philanthropic sectors. She joined ISGlobal in 2013 and currently leads the Malaria Elimination Initiative and the Steering Committee of the Malaria Eradication Scientific Alliance (MESA).
Previously, she spent nearly a decade as director of the infectious diseases division at the Bill & Melinda Gates Foundation, overseeing the product development and implementation of strategies to prevent and control infectious diseases. She also held senior positions at the U.S. National Institute of Allergy and Infectious Diseases and served as director of the PATH Malaria Vaccine Initiative. At present, she combines her responsibilities at ISGlobal with a position as ExxonMobil Malaria Scholar at Harvard TH Chan School of Public Health.
“As desperately needed COVID-19 vaccines become a reality, we need to take an active role in ensuring equity in the global rollout of these vaccines and continuing our work to prevent future pandemics,” commented Regina Rabinovich, who takes on the role of board chair from Axel Hoos, senior vice president and head for Oncology R&D at GlaxoSmithKline (GSK).
The Sabin Vaccine Institute
The Sabin Vaccine Institute is a non-profit with more than two decades of experience that advocates for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.